{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:10:50Z","timestamp":1759972250729,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal des Maladies Vasculaires"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jmv.2016.03.004","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T21:20:07Z","timestamp":1460668807000},"page":"197-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maladie thrombo-embolique veineuse au cours du cancer. Indication des h\u00e9parines de bas poids mol\u00e9culaires"],"prefix":"10.1016","volume":"41","author":[{"given":"M.","family":"Nou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmv.2016.03.004_bib0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patient with malignancy versus those without malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jmv.2016.03.004_bib0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ajh.20983","article-title":"Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism","volume":"82","author":"Anderson","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmv.2016.03.004_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jmv.2009.12.002","article-title":"Recommandations de bonne pratique\u00a0: pr\u00e9vention et traitement de la maladie thromboembolique veineuse en m\u00e9decine","volume":"35","author":"Mismetti","year":"2010","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.jmv.2016.03.004_bib0020","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jmv.2016.03.004_bib0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2016.03.004_bib0030","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"LITE trial investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jmv.2016.03.004_bib0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"CATCH investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jmv.2016.03.004_bib0040","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th consensus: American College of Chest Physician evidence based clinical practice guidelines","volume":"14","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jmv.2016.03.004_bib0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmv.2016.03.004_bib0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3747\/co.22.2587","article-title":"Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment","volume":"22","author":"Easaw","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jmv.2016.03.004_bib0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jmv.2016.03.004_bib0060","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jmv.2016.03.004_bib0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulations in patients with venous thromboembolism and cancer: a systematic review and meta-analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jmv.2016.03.004_bib0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12\u00a0months: the DALTECAN study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmv.2016.03.004_bib0075","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2013.51.7433","article-title":"Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the cancer-DACUS study","volume":"32","author":"Napolitano","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmv.2016.03.004_bib0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheter in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmv.2016.03.004_bib0085","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.seminoncol.2014.04.005","article-title":"Therapy for cancer-related thromboembolism","volume":"41","author":"Frere","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jmv.2016.03.004_bib0090","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmv.2016.03.004_bib0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2016.03.004_bib0100","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weigth heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmv.2016.03.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bulcan.2015.08.002","article-title":"M\u00e9thodes d\u2019\u00e9laboration des recommandations pour la pratique clinique (RPC) et fonctionnement de la plate-forme c\u0153ur vaisseaux cancer (PTF-CVC) dans l\u2019inter3C Vaucluse pays d\u2019Arles","author":"Debourdeau","year":"2015","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jmv.2016.03.004_bib0110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1160\/TH09-09-0667","article-title":"Endorse investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The Endorse global survey","volume":"103","author":"Bergmann","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2016.03.004_bib0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1684\/bdc.2014.1907","article-title":"Cancer et r\u00e9cidive thromboembolique veineuse\u00a0: non-respect des recommandations de traitement","volume":"101","author":"Mah\u00e9","year":"2014","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jmv.2016.03.004_bib0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jmv.2014.03.001","article-title":"Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study","volume":"39","author":"Sevestre","year":"2014","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.jmv.2016.03.004_bib0125","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1097\/MD.0000000000001235","article-title":"RIETE Investigators. Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism","volume":"94","author":"Farge","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jmv.2016.03.004_bib0130","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.rmr.2011.03.015","article-title":"Effet de la tinzaparine sur la mortalit\u00e9 du cancer bronchique non \u00e0 petites cellules op\u00e9r\u00e9","volume":"28","author":"Meyer","year":"2011","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.jmv.2016.03.004_bib0135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Journal des Maladies Vasculaires"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039804991630004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039804991630004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:14:12Z","timestamp":1759954452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S039804991630004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S039804991630004X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmv.2016.03.004","relation":{},"ISSN":["0398-0499"],"issn-type":[{"type":"print","value":"0398-0499"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie thrombo-embolique veineuse au cours du cancer. Indication des h\u00e9parines de bas poids mol\u00e9culaires","name":"articletitle","label":"Article Title"},{"value":"Journal des Maladies Vasculaires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmv.2016.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}